Palvella Therapeutics, Inc. Accounts Payable
Palvella Therapeutics, Inc. (PVLA) had Accounts Payable of $6.79 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-04
- 2026-06-30: Accounts Payable, Current $6.79M.
- 2026-03-31: Accounts Payable, Current $5.44M.
- 2025-12-31: Accounts Payable, Current $4.59M.
- 2025-09-30: Accounts Payable, Current $3.48M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $6.79M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $5.44M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $4.59M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $3.48M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $4.56M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $4.44M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $4.59M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $801.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $969.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $1.52M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $936.00K 10-K · filed 2025-03-31 | $3.37M 10-K · filed 2024-03-29 |
| 2023-09-30 | $2.82M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $7.60M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $5.83M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $4.15M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $3.64M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $1.90M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $4.50M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $8.61M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $3.56M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $2.31M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $3.47M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $1.79M 10-K · filed 2022-03-02 | |
| 2020-09-30 | $2.15M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $4.41M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $3.50M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $5.80M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $5.44M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $4.03M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $3.73M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $3.35M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $2.69M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $3.17M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $1.93M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $2.45M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $2.60M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $4.65M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $3.32M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $2.39M 10-K · filed 2018-03-15 | $2.39M 10-K · filed 2017-03-30 |
| 2015-12-31 | $1.06M 10-K · filed 2017-03-30 | |
| 2014-09-30 | $650.00 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $650.00 10-Q · filed 2014-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |